GE Healthcare Technologies Inc
NASDAQ:GEHC

  • LAST PRICE
    87.2900
  • TODAY'S CHANGE (%)
    -0.2600 (-0.2970%)
  • Bid / Lots
    87.2900/ 1
  • Ask / Lots
    88.8800/ 10
  • Open / Previous Close
    87.4000 / 87.5500
  • Day Range
    86.6800
    88.5000
  • 52 Week Range
    62.3500
    94.5000
  • Volume
    2,318,477

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 3, 2024

  • Aug 26, 2024

      Show headlines and story abstract

    • 10:52AM ET on Monday Aug 26, 2024 by MT Newswires
      Companies Mentioned: GEHC
      10:52 AM EDT, 08/26/2024 (MT Newswires) -- GE HealthCare Technologies (GEHC) said Monday that it received CE marks for its Vscan Air SL wireless handheld ultrasound system with Caption AI and for electrocardiogram-less Cardiac computed tomography sc...

    • 9:00AM ET on Monday Aug 26, 2024 by Dow Jones
      Companies Mentioned: GEHC

      Follow us on LinkedIn, X , Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com/ for more information.
      ____________________ (1) World Health Organization. Cardiovascular diseases (CVDs). June 11, 2021. Available at: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds ). Accessed July 2024. (2) Vaduganathan M, Mensah G, Turco J, et al. The Global Burden of Cardiovascular Diseases and Risk: A Compass for Future Health. JACC. 2022;80(25):2361-2371. https://doi.org/10.1016/j.jacc.2022.11.005 (3) The data was based on comparison between GE HealthCare's legacy products (16 ch and 64 ch scanner) and Revolution Ascend in the three institutions using a pilot product and selected routine head and body. The data set of this comparison was 838 exams for legacy products and 1387 exams for Revolution Ascend. The time saving value may not be effective for all institutions depending on the clinical practice. Defined the scan setting time is from "Open new patient" to "Confirm setting for Scout" (4) The required clicks are defined as clicks required to execute a scan from selecting a new patient till start scan. All associated clicks for and in clinical practice, number of the required clicks may vary depending on the circumstances, including but not limited to, the clinical task, exam type, clinical practice, and image reconstruction technique. (5) The data was based on comparison between GE HealthCare's legacy products (16 ch and 64 ch scanner) and Revolution Ascend in the three institutions using a pilot product and selected routine head and body. The data set of this comparison was 838 exams for legacy products and 1387 exams for Revolution Ascend. The time saving value may not be effective for all institutions depending on the clinical practice. Definition of entire exam time is from "Open new patient" to "Last primary recon completed" for Revolution Ascend and "Close exam" for legacy products. (6) INTERACT Touch with AVVIGO+ is pending CE Mark and not available for sale.

  • Aug 21, 2024

  • Aug 20, 2024

      Show headlines and story abstract

    • 8:30AM ET on Tuesday Aug 20, 2024 by Dow Jones
      Companies Mentioned: GEHC
      -- Published in Anesthesia and Analgesia, results from the multi-site trial evaluating End-tidal Control software provide compelling evidence for enhanced accuracy and efficiency of anesthesia delivery compared to conventional anesthetic gas delivery methods.1 -- End-tidal Control is the first FDA-approved software that automatically adjusts and maintains exhaled oxygen and exhaled anesthetic concentrations, with more accuracy in reaching the clinician's target versus manual control. The utilization of End-tidal Control software reduces manual adjustments by clinicians, enabling them to focus on time with their patients.2 -- Results support End-tidal Control's ability to reduce anesthetic agent usage, reducing greenhouse gas emissions and costs, compared to manual control. 1 CHICAGO--(BUSINESS WIRE)--August 20, 2024--

Peers Headlines